Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOMPERIDONE MALEATE

All products: general benefit

Other products in the same Health Canada class (A03FA) — coverage varies; not interchangeable

  • Metoclopramide (Metoclopramide HCL Injection): general benefit, Limited Use 481, 657, Not a benefit

Jamp Domperidone Tablets · DIN 02543435 · 10mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Domperidone Tablets · DIN 02543435 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-05-26 · brand JAMP DOMPERIDONE TABLETS · ATC A03FA03 DOMPERIDONE · form Tablet · route Oral · ingredients DOMPERIDONE (DOMPERIDONE MALEATE) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Domperidone Tablets: Formulary list price $0.0428/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0428 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103190 · Verify on the e-Formulary ↗ (DIN 02543435)

Source record
DIN 02543435: Jamp Domperidone Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 564000043; group id 676; item number 1690; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0428; ministry $0.0428 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543435 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103190
Interchangeable products
Apo-Domperidone · DIN 02103613 · $0.0428 Domperidone · DIN 02238341 · $0.0428 Domperidone · DIN 02350440 · $0.0428 Jamp-Domperidone · DIN 02369206 · $0.0428 Mar-Domperidone · DIN 02403870 · $0.0428 Motilium · DIN 00855820 · not recorded NRA-Domperidone · DIN 02561905 · $0.0428 PRZ-Domperidone · DIN 02462834 · $0.0428 Ran-Domperidone · DIN 02268078 · $0.0428 Teva-Domperidone · DIN 01912070 · $0.0428
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

METOCLOPRAMIDE HCL

· 8 products · Limited Use, codes 481, 657 (2), Listed, not a benefit (2), General benefit (4) · strengths: 5mg/mL, 5mg, 10mg · Inj Sol (Preservative Free), Tab

5-AMINOSALICYLIC ACID

· 17 products · General benefit (16), Listed, not a benefit (1) · strengths: 1g/Actuation, 500mg, 1.2g, 1g, 1g/100mL, 4g/100mL, 4g, 1000mg, 400mg · 14 Actuation-Foam Enema Canister Pk, Del-Release Tab, Delayed & ER Tab, DR Tab, Enema, Ent Tab, ER Tab, Rect Susp-Pk, Sup, Tab

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TEVA-DOMPERIDONE (domperidone maleate) is indicated for: • Symptomatic management of upper gastrointestinal motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis. • Prevent gastrointestinal symptoms associated with the use of dopamine agonist antiparkinsonian agents. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TEVA-DOMPERIDONE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (> 60 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX and 4.1 Dosing Considerations). https://pdf.hres.ca/dpd_pm/00077081.PDF PM date: JAN 24, 2011 Source product: TEVA-DOMPERIDONE; DIN 01912070; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.